Table 1.
Baseline characteristics.
| N = 59 | |
|---|---|
| Age, median (range) | 68 (48–83) |
| Sex (%) | |
| Male | 34 (58) |
| Female | 25 (42) |
| Race (%) | |
| White | 53 (90) |
| Black | 5 (8) |
| Declined to answer | 1 (2) |
| AL subtype (%) | |
| Kappa | 13 (22) |
| Lambda | 46 (78) |
| 2004 stage (%) | |
| I | 14 (24) |
| II | 17 (29) |
| IIIa | 18 (30) |
| IIIb | 8 (14) |
| Missinga | 2 (3) |
| 2012 stage (%) | |
| 1 | 9 (14) |
| 2 | 18 (28) |
| 3 | 20 (36) |
| 4 | 10 (16) |
| Missinga | 2 (6) |
| Mean dFLC (SD), mg/L | 215.7 (224.6) |
| Mean NT-proBNP (SD), pg/mL | 5310.3 (8445.1) |
| Mean troponin T (SD), ng/mL(N = 34) | 0.07 (0.09) |
| Mean hs troponin T (SD), ng/L (N = 23) | 12.6 (44) |
| Cardiac (%) | 39 (66) |
| Renal (%) | 34 (58) |
| Number of organs (%) | |
| 1 | 21 (36) |
| 2 | 23 (39) |
| ≥3 | 15 (25) |
| First line treatment | |
| Cylcophosphamide/bortezomib/dexamethasone | 44 (75%) |
| Cyclophsphamide/ixazomib/dexamethasone | 2 (3%) |
| Cylcophosphamide/lenalidomide/dexamethasone | 1 (2%) |
| Bortezomib/dexamethasone | 2 (3%) |
| Daratumumab | 1 (2%) |
| Stem cell transplant | 5 (9%) |
| Unknown | 4 (6%) |
dFLC—difference between involved and uninvolved free light chains.
aTwo patients had missing cardiac biomarkers prior to starting therapy.